196 related articles for article (PubMed ID: 34253674)
21. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
[TBL] [Abstract][Full Text] [Related]
22. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
23. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
24. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment.
Ellerbroek N; Martino S; Mautner B; Tao ML; Rose C; Botnick L
Breast J; 2003; 9(2):74-8. PubMed ID: 12603378
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
Yazilitas D; Sendur MA; Karaca H; Ozdemir N; Aksoy S; Berk V; Yazici O; Ozturk B; Ozkan M; Zengin N; Altundag K
Asian Pac J Cancer Prev; 2015; 16(4):1471-7. PubMed ID: 25743817
[TBL] [Abstract][Full Text] [Related]
26. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
27. Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer.
Joris S; Fontaine C; Decoster L; Vanacker L; Schallier D; De Grève J
Breast J; 2019 Jul; 25(4):663-666. PubMed ID: 31074007
[TBL] [Abstract][Full Text] [Related]
28. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.
Tahover E; Segal A; Isacson R; Rosengarten O; Grenader T; Gips M; Cherny N; Heching NI; Mesika L; Catane R; Gabizon A
Anticancer Drugs; 2017 Aug; 28(7):787-794. PubMed ID: 28562379
[TBL] [Abstract][Full Text] [Related]
29. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
Gbabe OF; Okwundu CI; Dedicoat M; Freeman EE
Cochrane Database Syst Rev; 2014; (9):CD003256. PubMed ID: 25313415
[TBL] [Abstract][Full Text] [Related]
30. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Lyman GH; Dale DC; Crawford J
J Clin Oncol; 2003 Dec; 21(24):4524-31. PubMed ID: 14673039
[TBL] [Abstract][Full Text] [Related]
31. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Vernieri C; Milano M; Mennitto A; Maggi C; Ferrari B; Rinaldi L; Mennitto R; Stefanetti C; Re B; Mariani G; Bianchi G; Capri G; de Braud F
Breast Cancer Res Treat; 2017 Sep; 165(2):365-373. PubMed ID: 28616768
[TBL] [Abstract][Full Text] [Related]
33. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
[TBL] [Abstract][Full Text] [Related]
34. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
Liutkauskiene S; Grizas S; Jureniene K; Suipyte J; Statnickaite A; Juozaityte E
BMC Cancer; 2018 Apr; 18(1):453. PubMed ID: 29678165
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
36. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.
Barroso-Sousa R; Paes FR; Vaz-Luis I; Batista RB; Costa RB; Losk K; Camuso K; Metzger-Filho O; Hughes ME; Bunnell CA; Golshan M; Winer EP; Lin NU
Breast; 2016 Dec; 30():136-140. PubMed ID: 27721193
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Cadoo KA; Kaufman PA; Seidman AD; Chang C; Xing D; Traina TA
Clin Breast Cancer; 2018 Dec; 18(6):433-440.e1. PubMed ID: 29895438
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.
Yerushalmi R; Goldvaser H; Sulkes A; Ben-Aharon I; Hendler D; Neiman V; Ciuraru NB; Bonilla L; Amit L; Zer A; Granot T; Rizel S; Stemmer SM
PLoS One; 2014; 9(10):e107273. PubMed ID: 25330205
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
40. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
